Acrivon’s ACR-7280 shows complete tumor regression in AML mouse models

• Acrivon Therapeutics advanced oral CDK11 inhibitor ACR-7280 toward an FDA investigational new drug filing in the first half of 2027.
• IND-enabling studies are underway for the candidate, selected using the proprietary AP3 drug discovery platform.
• Preclinical testing showed complete tumor regression in aggressive acute myeloid leukemia mouse models.
• ACR-7280 demonstrated strong synergy with venetoclax and menin inhibitors across several leukemia models.
• Initial development will focus on acute myeloid leukemia, both as a single agent and in combination.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acrivon Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610200830PRIMZONEFULLFEED9849175) on October 20, 2026, and is solely responsible for the information contained therein.